Sorafenib in Newly Diagnosed High Grade Glioma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2011 by University Hospital, Geneva.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
Andreas F. Hottinger, University Hospital, Geneva
ClinicalTrials.gov Identifier:
NCT00884416
First received: April 17, 2009
Last updated: August 25, 2011
Last verified: August 2011

April 17, 2009
August 25, 2011
March 2009
December 2011   (final data collection date for primary outcome measure)
Safety and tolerability of sorafenib in combination with radiation and temozolomide chemotherapy [ Time Frame: 35 weeks ] [ Designated as safety issue: Yes ]
Safety and tolerability of sorafenib in combination with radiation and temozolomide chemotherapy in patients with newly diagnosed high grade glioma
To evaluate safety and tolerability of sorafenib in combination with radiation and temozolomide chemotherapy in patients with newly diagnosed high grade glioma [ Time Frame: 35 weeks ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT00884416 on ClinicalTrials.gov Archive Site
  • Maximum Observed Plasma Concentration (Cmax) and Area under the curve (AUC) of sorafenib and temozolomide [ Time Frame: 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post dose ] [ Designated as safety issue: No ]
  • Response rate [ Time Frame: 35 weeks ] [ Designated as safety issue: No ]
  • Time to treatment failure [ Time Frame: 20 months ] [ Designated as safety issue: No ]
  • 6 month progression-free survival [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Event free survival [ Time Frame: 20 months ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: 20 months ] [ Designated as safety issue: No ]
  • Pharmacokinetic of sorafenib and temozolomide [ Time Frame: 35 weeks ] [ Designated as safety issue: No ]
  • Response rate [ Time Frame: 35 weeks ] [ Designated as safety issue: No ]
  • Time to treatment failure [ Time Frame: 35 weeks ] [ Designated as safety issue: No ]
  • 6 month progression-free survival [ Time Frame: 35 weeks ] [ Designated as safety issue: No ]
  • Event free survival [ Time Frame: 35 weeks ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: 35 weeks ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Sorafenib in Newly Diagnosed High Grade Glioma
Phase I Dose Finding Study of Sorafenib in Combination With Radiation Therapy and Temozolomide as a First Line Treatment of Patients With High Grade Glioma

This is a phase I study to evaluate the safety and tolerability of Sorafenib in combination with Temodar and radiation therapy in patients with newly diagnosed high grade glioma (glioblastoma, gliosarcoma, anaplastic astrocytoma and anaplastic oligodendroglioma or oligoastrocytoma). The mechanism of action of sorafenib, an oral multikinase inhibitor, makes it an interesting drug to investigate in the treatment of patients with high grade glioma as this agent has anti-angiogenic activity and inhibits other pathways such as Ras, Platelet-derived growth factor (PDGF) and fms-like tyrosine kinase receptor-3 (Flt-3), which are potential targets against gliomas.

Up to 18 patients will be included in this phase I study. The primary goal of this study will be to establish the maximum tolerated dose of sorafenib when used in combination with temozolomide and radiation therapy. Secondary goals of this study include: response rate, time to treatment failure, 6 month progression-free survival, event free survival and overall survival. A correlative study will investigate the pharmacokinetics of sorafenib used in combination with radiation therapy and temozolomide.

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Glioblastoma
  • Gliosarcoma
  • Anaplastic Astrocytoma
  • Anaplastic Oligoastrocytoma
  • Anaplastic Oligodendroglioma
Drug: Sorafenib dose escalation
Sorafenib dose escalation scheme: 3 first patients: 200 mg/d, if dose limiting toxicities (DLT) not reached: 3 patients at 200 mg BID, if no DLT reached: 3 patients at 400 mg bid
Experimental: Sorafenib dose titration
Intervention: Drug: Sorafenib dose escalation
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
18
December 2011
December 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histological documentation of newly diagnosed malignant glioma
  • ECOG performance status of 0 or 1
  • Age ≥18
  • Life expectancy of at least 12 weeks
  • Hemoglobin ≥ 9.0 g/dl
  • Granulocyte count ≥1.5 X 10^9/L
  • Platelet count ≥100 X 10^9/L
  • SGOT ≤ 2.5X upper limit of normal (ULN)
  • SGPT ≤ 2.5X upper limit of normal (ULN)
  • Alkaline phosphatase ≤4x ULN
  • Serum creatinine ≤1.5X ULN
  • Bilirubin ≤1.5X ULN
  • Spontaneous PT-INR/PTT < 1.5x upper limit of normal (patients on therapeutic anticoagulation will be allowed to participate.
  • Patients must be on a stable or decreasing dose of corticosteroids for at least 2 weeks
  • Patient for whom a first line treatment with temozolomide and radiotherapy is adequate
  • Prophylactic anti-emetic, pentamidine inhalation / co-trimoxazole and anticonvulsants are allowed
  • All patients must sign written informed consent.

Exclusion Criteria:

  • Prior treatment for high grade glioma
  • Previous exposure to Ras pathway inhibitors
  • Other concurrent active malignancy (with the exception of cervical carcinoma in situ or non melanoma carcinoma of the skin, superficial bladder tumor [Ta, Tis & T1] or any cancer curatively treated > 3 years prior to study entry).
  • Serious medical or psychiatric illness that would, in the opinion of the investigator, interfere with the prescribed treatment, including but not limited to: Congestive heart failure > NYHA class 2, active CAD, cardiac arrythmias requiring anti-arrythmic therapy or uncontrolled hypertension within the last 12 months
  • Any condition limiting the patient's judgment capacity
  • History of HIV infection, chronic hepatitis C or B as well as clinically active infections (> grade 2 NCI-CTC version 3.0)
  • History of organ allograft
  • Renal dialysis
  • Evidence or history of bleeding diathesis
  • Major surgery within 4 weeks of start of study treatment, except for neurosurgical resection
  • Autologous bone marrow transplant or stem cell rescue within 4 months of study
  • Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of study results.
  • Medical condition that prevents the patient from swallowing pills
  • Use of biologic response modifiers, such as G-CSF within 3 week of study entry.
  • Pregnant or breast-feeding women.
  • Refusal to use effective contraception. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and for at least 3 months after administration of study medication.
  • Known or suspected allergy to the investigational agent or any agent given in association with this trial.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Switzerland
 
NCT00884416
08-122, 2009DR1029, 13031
Yes
Andreas F. Hottinger, University Hospital, Geneva
University Hospital, Geneva
Bayer
Principal Investigator: Pierre-Yves Dietrich, MD Department of oncology, Geneva University hospital
University Hospital, Geneva
August 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP